January 20, 2021 5:56pm
Investors hope that the “coming” $1.9 trillion Covid-19 aid plan will stimulate economic recovery
Numbers based facts speak better then opinion as I see answers in numbers
Pre-open indication: 5 HITs and 6 MISS <wait for the reverses>
Are we here to make money or see share pricing erode as earnings LPS (loss-per-share) season is about to begin?
Subscription is coming, it’s not conscription but, an offer to join our collective of like-minded investor profiting!
The Dow closed UP +257.86 points (+0.83); the S&P closed UP +52.94 points (+1.39%) while the Nasdaq closed UP +260.07 points (+1.97%)
Henry’omics:
Indexes rallied to a record close as President Biden was sworn into office
Today, shares of clinical-stage biopharmaceutical company Caladrius Biosciences (CLBS) took off by a whopping 110% but then closed +77.3%.
- However, the surge did not come off the back of a treatment’s regulatory approval or the release of positive clinical trial results.
- Seemingly more prosaic, investors appeared to cheer the news that the company has treated its first patient in the P2b FREEDOM Trial of CLBS16, the small biotech’s candidate for the treatment of coronary microvascular dysfunction (CMD).
- https://finance.yahoo.com/news/caladrius-stock-buy-now-know-192558510.html <TipRanks>
Sentiment and COVID-19 infections:
A slew of strong quarterly results also boosted sentiment as All three averages also touched their intraday highs during the session.
President Biden announced a nationwide vaccine campaign to speed up the rollout.
Infection cases <Million>: never to forget …
- Wednesday 24.25 M cases,
- Wednesday’s death rate totaled 401,797 <Johns Hopkins University>
This a.m.’s post, “expectation formulates an outlook that defines possible outcomes. Markets will take a back seat to inauguration, a listening day” … https://www.regmedinvestors.com/articles/11728
RegMed/Stem/Cell and Gene therapy’s 35 covered equities’ Advance/Decline (A/D) lines: progressions and regressions …
- Wednesday opened negative at 13/18 and 4 flats, flipped neutral at the mid-day to 17/17 and 1 flat, closing negative at 16/18 and 1 acquired;
- Tuesday opened positive at 27/6 and 2 flats, stayed positive at the mid-day at 20/13 and 2 flats, closing positive at 18/14, 2 flats and 1 acquired;
- Monday was holiday
Pre-open indication:
- 5 HITs <SELL into Strength: Fate Therapeutics (FATE -$5.30), Intellia therapeutics (NTLA -$3.12), Pluristem (PSTI +$0.02), Mesoblast (MESO +$0.06), SELL post offering: Editas Medicine (EDIT -$0.35); 6 MISS < Maintaining SELL: Biostage (BSTG +$0.01 with 1,277 shares traded with after Tuesday’s +$0.06 with 18,420 shares traded (a whole lot of “pumpin’ going-on); BUY: bluebird bio (BLUE -$1.63), BUY: CRISPR Therapeutics (CRSP -$8.52); SELL: Homology Medicine (FIXX +$0.25), Ionis Pharmaceuticals (IONS +$1.51), Mesoblast (MESO +$0.06)>
Key metrics:
- Sector volume was LOW with 5 of the 16-upside having higher than the 3-month average volume with the increased volume of 6 of 18-downside having higher than the 3-month average volume;
- Wednesday’s percentage (%) of the 16-upside were +0.25% (PSTI) to +77.30% (CLBS) while the 18-downside ranges from -0.17% (SLDB) to-10.20% (VSTM);
There are clear winners — and losers — heading into the first month of 2021.
52-week high:
- Cellectis SA (CLLS) reached a 52-week high of $34.59, then closed down -$0.16 to $33.09
Jumping with share pricing momentum:
- Alnylam Pharmaceuticals (ALNY), Adverum Biotechnologies (ADVM), Sage Therapeutics (SAGE), Ionis Pharmaceuticals (CLBS), Precigen (PGEN) to name 5 of the 16 inclining of the 35 covered
Hammered in today’s market:
- ReNeuron (RENE.L), CRISPR Therapeutics (CRSP), Fate Therapeutics (FATE), Ultragenyx (RARE), Regenxbio (RGNX) to name 5 of the 18 declining of the 35 covered
Wednesday’s (10 of 16) incliners:
- Alnylam Pharmaceuticals (ALNY +$2.56 after Tuesday’s +$2.05);
- Adverum Biotechnologies (ADVM +$1.75 after Tuesday’s +$0.80);
- Sage Therapeutics (SAGE +$1.66 after Tuesday’s -$1.83);
- Ionis Pharmaceuticals (IONS +$1.51 after Tuesday’s -0.25);
- Precigen (PGEN +$1.31);
- Caladrius Biosciences (CLBS +$1.26);
- AxoGen (AXGN +$1.02 after Tuesday’s -$0.33);
- uniQure NV (QURE +$0.78 after Tuesday’s +$0.57);
- Vericel (VCEL +$0.75);
- Bellicum Pharmaceuticals (BLCM +$0.70);
Wednesday’s (10 of 18) decliners:
- ReNeuron (RENE.L -$9.50 after Tuesday’s flat);
- CRISPR Therapeutics (CRSP -$8.52 after Tuesday’s -$1.59);
- Fate Therapeutics (FATE -$5.30 after Tuesday’s +$0.72);
- Ultragenyx (RARE -$3.72 after Tuesday’s +$0.90);
- Regenxbio (RGNX -$3.22 after Tuesday’s -$0.49);
- Intellia Therapeutics (NTLA -$3.12 after Tuesday’s +$1.79);
- Global Blood Therapeutics (GBT -$2.59 after Tuesday’s +$0.93);
- bluebird bio (BLUE -$1.63 after Tuesday’s -$1.02);
- BioLife Solutions (BLFS -$0.52 after Tuesday’s +$0.79);
- Chinook Therapeutics (KDNY -$0.48);
Closing 1 -Stemline Therapeutics (STML – acquired)
Stats:
The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:
- Wednesday, the IBB closed up +0.10% and XBI closed down -0.06%
- Tuesday, the IBB closed up +1.93% and XBI closed up +1.64%
- Monday was holiday
The CBOE Volatility Index (VVIX: INDEX) tracked:
- Wednesday was down -1.66 points or -7.14% at 21.58
- Tuesday was down -1.10 points or -4.52% at 23.24
- Monday was a holiday
Upside volume:
- Wednesday: 5 out of the 16-upside had higher than the 3-month average volume;
- Tuesday: 5 out of the 18-upside had higher than the 3-month average volume;
- Monday was a holiday
Downside volume:
- Wednesday: 6 out of the 18-downside had higher than the 3-month average volume;
- Tuesday: 7 out of the 14-downside had higher than the 3-month average volume;
- Monday was a holiday
Percentage (%) movement/range statistics: a 360 degrees comparison of % and pricing
- Wednesday’s percentage (%) of the 16-upside were +0.25% (PSTI) to +77.30% (CLBS) while the 18-downside ranges from -0.17% (SLDB) to-10.20% (VSTM);
- Tuesday’s percentage (%) of the 18-upside were +0.63% (FATE) to +15.57% (BSTG) while the 14-downside ranges from -0.07% (KDNY) to -6.64% (SLDB);
- Monday was a holiday
January, the 1st month of Q1 …
Wednesday closed negative with 16 advancers, 18 decliners and 1 acquired
Tuesday closed positive with 18 advancers, 14 decliners, 2 flats and 1 acquired
Monday (1/18) was a holiday
Friday closed negative with 10 advancers, 24 decliners and 1 acquired
Thursday closed positive with 27 advancers, 7 decliners and 1 acquired
Wednesday closed positive with 10 advancers, 21 decliners and 4 flats
Tuesday closed positive with 21 advancers, 13 decliners and 1 flat
Monday (1/11) closed negative with 13 advancers, 20 decliners and 2 flats
Friday closed negative with 16 advancers, 18 decliners and 1 flat
Thursday closed positive with 31 advancers, 2 decliners and 2 flats
Wednesday closed positive with 22 advancers, 12 decliners and 1 flat
Tuesday closed positive with 19 advancers, 14 decliners and 2 flats
Monday (1/4) closed positive with 26 advancers, 7 decliners and 2 flats
The Bottom Line: There is STILL a short-term tone in the sector – “our’ universe of RegMed, stem, cell and gene therapy equities.
The more important question is whether sector equities (not when) will rise and why they will appreciate – a P2 from CLBS jumped +77.30% - watch it drop in the aftermarket <-$0.03 so far>?
I keep reiterating, “sector volatility remains fluid … as I had stated, “you should take some profits even if some money is left on the table – safety is cash in your pocket of portfolio!”
To make money in this sector, one has to know when to get out and which individual equity you should stay in!
Forewarned … Earnings LPS (los-per-share) season is coming quickly – my advice, trim and skim!!
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
